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Abstract
The emergence of carbapenem-resistant  Acinetobacter baumannii represents a major 
problem in the heath settings. Infections with such pathogens are often associated with high 
rate of morbidity and mortality. The aim of the present study was to  investigate the clonal 
relatedness associated with genes encoding β-lactamases and metallo-β-lactamases associated 
with carbapenem resistance in clinical isolates of  A. baumannii from diabetic patients from 
different  regions  in  Saudi  Arabia.  A total  of  64  non-repetitive  carbapenem  resistant  A. 
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baumannii clinical isolates were collected from sixteen different regions in Saudi Arabia from 
patients in intensive care units. Isolates were identified phenotypically by Vitek 2 compact 
system and genotypically by amplification of intrinsic blaOXA-51-like gene by PCR. The 
target sequences were amplified by PCR and the clonal diversity of the isolates was explored 
by PFGE. The resistance pattern of the tested isolates was determined by Vitek 2 compact 
system and the minimum inhibitory concentrations of imipenem, meropenem, tigecycline and 
colistin were determined by Etest strips. The results of the current study revealed that the 
prevalence of imipenem and meropenem resistance was 92% and 96%, respectively, while the 
vast  majority  of  the  isolates  were  susceptible  to  tigecycline  and  colistin  (97% each).  In 
addition, the prevalence of blaOXA-23, blaOXA-40, blaVIM and blaSPM was 53.1%, 29.7%, 92.2% and 
28.1,  respectively,  while  blaIMP,  blaSIM and  blaGIM were  not  detected.  Moreover,  ISAba1, 
ISAba2 and ISAba3 were amplified from 58 (90.6%), 6 (9.4%) and 13 (20.3%) of the tested 
isolates, respectively. PFGE results showed that the tested isolates were clustered in thirteen 
groups. Clone H was the dominant clone containing 20 isolates from four hospitals followed 
by clone  C  and  F  containing  11  isolates  each  from 3  and  6  hospitals,  respectively.   In 
conclusion, blaVIM and blaOXA-23 were the most prevalent genes in the carbapenem resistant A. 
baumannii isolates  under  investigation  while  ISAba1 was  the  most  common  insertion 
sequence. Early recognition of the epidemic clone is very helpful to prevent its dissemination 
by application of strict infection control measures. 
KEYWORDS: Acinetobacter baumannii; Clonal diversity; Saudi Arabia; Diabetic patients
Introduction
Acinetobacter baumannii (A. baumannii)  is  an aerobic,  non-motile,  non-fermenting Gram-
negative  opportunistic  pathogen  that  is  playing  a  major  role  in  nosocomial  infections  of 
immunecompromised patients.1 It  is  considered  one  of  the  six  most  important  multidrug-
resistant microorganisms in the hospitals especially in the intensive care units. Infections with 
such pathogen are often associated with high rate of morbidity and mortality.2 A. baumannii is 
intrinsically has low susceptibility to different antimicrobial agents.3 In the last decade, many 
multi-drug resistant (MDR) and extensive-drug resistant A. baumannii were isolated globally4, 
regionally5,6 and  locally7,8.  Nowadays,  MDR  A.  baumannii is  among  the  most  difficult 
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pathogens to treat.9 Carbapenems represent the main therapy for the serious infections caused 
by  such  pathogens.10,11 Unfortunately,  a  dramatic  increase  of  carbapenem  resistant  A. 
baumannii isolates has been recorded in the recent years.6,7 
Carbapenem resistance of  A. baumannii is mainly mediated by: (i) changes in porin 
proteins, (ii) development of efflux pumps, (iii) modification of penicillin-binding proteins, 
and production of different types of β-lactamases.12 According to Ambler classification, there 
are four classes of β-lactamases (A, B, C and D). Classes A, C and D are serine type enzymes 
while class B is metallo-type enzymes (metallo-β-lactamases, MBLs) which require zinc for 
their catalytic activity.13 In  A. baumannii,  MBLs (class B) and OXA-type carbapenemases 
(class D) mainly mediate resistance to carbapenems and to a lesser extent class A e.g. KPC.1 
Since the discovery of the first OXA-type carbapenemases in 1993 in  A. baumannii 
isolate  from  Scotland14,  many  types  were  discovered  and  the  number  of  OXA-type  β-
lactamases exponentially increases.15 Five main groups of OXA carbapenemase are involved 
in the resistance of  A. baumannii: OXA-23-like, OXA-40-like, OXA-51-like, OXA-58-like 
and OXA-143 enzymes.1 The genes coding these enzymes are regulated by upstream insertion 
sequences (IS) specifically ISAba1, ISAba2, ISAba3 and IS18.1,16,17 These insertion elements 
play a  major role in the expression of such genes.18,19 Chromosomally located blaOXA-51-like 
genes  are  intrinsically  present  in  all  A.  baumannii stains.20 In  addition  to  OXA 
carbapenemases, three MBLs have been detected in A. baumannii namely IMP, VIM and SIM 
types.17  In Saudi Arabia, the data regarding the mechanism of carbapenem resistance in  A. 
baumannii is limited although some reports are recently published.7,8 
The aim of the present study was to  investigate  the prevalence of various genes and 
the  different  insertion  sequences  associated  with  carbapenem resistance  in  A.  baumannii 
clinical  isolates  from  sixteen  different  regions  in  Saudi  Arabia.  In  addition,  the  clonal 
relatedness of such clinical isolates was investigated.    
 Methods
Bacterial isolates
Sixty four non-repetitive A. baumannii clinical isolates were collected from different clinical 
specimens from patients  in  intensive care  units.  The isolates  were  collected from sixteen 
different regions in Saudi Arabia between January and November 2012. No ethical approval 
was  required  because  samples  were  collected  as  a  routine  and  standard  patient  care. 
Conventional microbiological methods were performed for preliminarily identification of the 
isolates and the identification was confirmed by the Vitek 2 compact system (BioMerieux, 
Marcy  L’Etoile,  France)  according  to  the  guidelines  of  the  manufacturer.  For  molecular 
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confirmation  of  the  Vitek  2  compact  system identification,  PCR was  used  to  detect  the 
intrinsic blaOXA-51-like gene. The primers used for amplification of such gene were depicted in 
Table 1. 
Antimicrobial susceptibility testing
The resistance pattern of the tested isolates was determined by Vitek 2 compact system and 
confirmed by agar diffusion assay21 against imipenem, meropenem, tigecycline and colistin. 
Antibiotic discs were purchased from Oxoid Ltd, UK. The minimum inhibitory concentrations 
(MICs) of the previously mentioned four antimicrobial agents were determined by Etest strips 
(AB Biodisk, Solna, Sweden) according to instructions of the manufacturer. All experiments 
were carried out in triplicate.
Detection of blaOXA-23 and blaOXA-40 genes
Polymerase  chain  reaction  (PCR)  was  used  to  amplify  the  genes  encoding  OXA-type 
carbapenemases (blaOXA-23,  blaOXA-40) and MBLs (blaVIM,  blaSIM, blaGIM, blaIMP and blaSPM) as 
previously described11,22-24 using the primers depicted in Table 1.
Molecular typing by PFGE
Sixty  four  A.  baumannii clinical  isolates  were  typed  by  PFGE  analysis  as  previously 
described.25 DNA obtained from bacteria was digested using Apa1 restriction endonuclease 
(Promega, Southampton, UK), and DNA fragments were separated on 1% agarose gel in 0.5× 
TBE buffer using the CHEF-RDII apparatus (Bio-Rad, UK). The conditions used were the 
following: pulse time 5-35s at field strength of 6v/cm for 24h at 37C. The gel was stained by 
ethidium bromide and then the digital images were captured by Gel doc2000 (Bio-Rad, UK). 
All isolates were analyzed using Bionumerics software version 6.5.  Isolates that clustered 
together with a similarity of >85% were considered to belong to the same PFGE type.
 
Results
Sixty four non-repetitive  A. baumannii clinical isolates (coded DM001 to DM064) 
were collected from sixteen different regions in Saudi Arabia. The isolates were cultured from 
different  clinical specimens of diabetic patients admitted to ICUs. Thirty four patients (53%) 
were males while the female patients represented 47% (30/64). Most isolates were collected 
from respiratory tract clinical specimens (41 out of 64, 64%) while the rest of the isolates 
were obtained from infected blood, urine, abdomen and skin. Vitek II compact system was 
4
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
used to identify the isolates and the identification was confirmed after amplification of the 
intrinsic blaOXA-51-like gene by PCR. 
All  isolates  showed  resistance  to  at  lease  one  of  the  two  tested  carbapenems 
(imipenem and  meropenem)  as  shown  in  Figure  1.  No  significant  different  between  the 
prevalence of imipenem (59 out of 64, 92%) and meropenem (62 out of 64, 96%) resistance 
among the tested isolates as shown in Table 2. On the other hand, the majority of the isolates 
showed susceptibility to tigecycline and colistin, 97% each as mentioned Table 2. 
The prevalence of the different genes coding two OXA carbapenemases (OXA-23 and 
OXA-40), five MBLs (VIM, IMP, SPM, SIM and GIM) and the different insertion sequences 
(ISs)  was calculated  after  amplification of  the  target  genes  by PCR and the results  were 
depicted in Table 3. Thirty four (53.1%) and nineteen (29.7%) isolates harbored blaOXA-23 and 
blaOXA-40,  respectively.  Only  two  MBLs  were  detected  in  the  isolates  where  blaVIM was 
significantly more prevalent than blaSPM, 59/64 (92.2%) and 18/64 (28.1), respectively. On the 
other hand, blaIMP, blaSIM and blaGIM were not detected in any of the tested isolates as shown in 
Table 3. Although IS18 was completely absent from all the tested isolates, ISAba1, ISAba2 
and ISAba3 were amplified from 58 (90.6%), 6 (9.4%) and 13 (20.3%) of the tested isolates, 
respectively, as shown in Table 3.
PFGE was applied to study the clonal diversity and relatedness of the tested isolates.  
The  discrimination  power  of  PFGE  technique  was  express  by  dice  coefficient  via 
BioNumerics software version 6.5. Figure 1 shows the clustering of thirteen groups from A to 
M of PFGE types comprise the ID number (isolate code), sex, locations, β-lactamase of OXA-
23, OXA-40, insertion sequences (ISAba1, ISAba2, ISAba3 and IS18) and MBLs (VIM, SIM, 
GIM,  IMP  and  SPM).  All  detected  PFGE  patterns  demonstrate  the  genetic  similarity 
coefficient  ranged  from  70%  to  100%.  Epidemic  isolates  that  clustered  together  with  a 
similarity of more than 85% were considered to present the same PFGE type. Clone C, F and 
H included 11, 11 and 20 PFGE types, respectively, with genetic similarity ranges from 92 to 
100%,  88  to  100%  and  89  to  100%  respectively,  and  have  shared  4,  3  and  6  cities, 
respectively, as shown if Figure 1. In addition, table 4 showed the diversity of the thirteen 
clones and the mechanism of resistance in relation to the cities from which the isolates were 
collected. Nine and five different clones were detected in 34 and 6 isolates from Riyadh and 
Almandine, respectively. 
Discussion
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The emergence and global distribution of carbapenem resistant A. baumannii represent 
a  major  problem in  the  health  care  setting  specially  ICUs. A.  baumannii is  a  notorious 
opportunistic pathogen mainly associated with hospital-acquired infections.26 This pathogen 
causes serious hospital acquired infections associated with high mortality rate particularly in 
immunocompromised patients. Moreover, very limited therapeutic options (e.g. colistin and 
tigecycline) are available for treatment of infection cause by such pathogens.27
In the present study, sixty four A. baumannii clinical isolates (based on the presence of 
blaoxa-51-like gene) were collected from tertiary care hospitals located in sixteen different cities in 
Saudi Arabia. These cities are distributed in many provinces of the Kingdom. The majority of 
the isolates were recovered from respiratory tract secretions of diabetic patients. In the last 
few  years,  emergence  of  carbapenem  resistance  in  Gram  negatives  has  been  observed 
worldwide.  This  phenomenon  is  mostly  related  to  the  spread  of  different  types  of  β-
lactamases.28 A.  baumannii is  an  organism  that  appears  to  have  the  ability  to  develop 
antibiotic  resistance  very  rapidly.3 Carbapenems  were  the  drug  of  choice  for  treating 
infections caused by MDR A. baumannii, however, resistance to such antimicrobial agents is 
now a common occurrence and pan-drug resistant strains are beginning to emerge.1 In  A. 
baumannii, the main carbapenem hydrolyzing β-lactamases are OXA-type carbapenemases 
(Ambler class D β-lactamases) and MBLs (class B β-lactamases).28 
In the present study, the vast majority of the isolates showed susceptibility to 
colistin and tigecycline (97%). Higher tigecycline resistance rate (9.7%) was recently 
recorded in Riyadh region29 while  susceptibility  to colistin in the current study is in 
accordance with different previously published reports.29-32 In Iran, Shahcheraghi et al 
20116 reported that 12% of A. baumannii isolates showed resistance to colistin while in 
another recently published article,  no colistin resistance was observed in 104 clinical 
isolates.10 Although many colistin and tigecycline resistant A. baumannii pathogens were 
recently  isolated33,34,  these  two  antimicrobial  agents  remain  the  drug  of  choice  for 
combating infections caused by carbapenem resistant A. baumannii.  
The prevalence of OXA-23 in the current study was 53.1% which is comparable with 
recently published result from Egypt (50%)32 and from India (47.9%)35. Higher prevalence of 
OXA-23 (100% and 80.4%) was detected in CRAB isolates from Riyadh36 and the Eastern 
region of Saudi Arabia8,  respectively, from Taiwan (92.9%)37,  from Iran (84%6 and 77.9%10) 
and from Columbia38 (75%). On contrary, only two isolates carried  blaOXA-23  out of 40 (5%) 
isolates collected from Kuwait5 while only one isolate out of 92 (1.1%) isolated from Taiwan 
harbored such gene.39 On the other hand, OXA-40 was amplified from 29.7% of the tested 
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isolates in the present work. This carbapenemase was not detected in any of the tested isolates 
(n=253) from Riyadh.36  While blaOXA-40 was the most prevalent acquired gene (57.6%) in 59 
isolates from Spain, none of such isolates harbored blaOXA-23.40 In addition, 7.5%, 19.2% and 
22.9% of  isolates  from Egypt32,  Iran10 and  India35,  respectively,  contained  OXA-40.  Co-
existence  of  both  blaOXA-23  and  blaOXA-40  was not  detected  in  any of  the tested  isolates.  In 
contrast, 45% and 16.4% CRAB isolates collected from Egypt32 and Iran10,  respectively, co-
produced both enzymes OXA-23 and OXA-40.
Beside OXA carbapenemases, MBLs were detected in many of the tested isolates in 
the present work. VIM and SPM were the only two MBLs detected where their prevalence 
was 92.2% (59 out of 64) and 28.1% (18 out of 64), respectively, while the other three MBLs 
(IMP, GIM and SIM) were completely absent. Lower prevalence of MBLs (6%) was recorded 
in Iran6 where only blaSPM  was detected while  blaVIM was completely absent. In addition, 46 
carbapenem resistant A. baumannii (CRAB) clinical isolates from the Eastern region of Saudi 
Arabia  harbored  neither  blaVIM nor  blaIMP.8 Moreover,  MBL encoding  genes  were  not 
amplified from any of 40 clinical isolates from Egypt.32  On contrary, most CRAB isolates 
from Kuwait (72.5%, 29 out of 40 isolates) carried bla genes coding VIM and IMP MBLs.5
Our results revealed that ISAba1 was the most prominent (90.6%) insertion element in 
the tested isolates followed by ISAba3 (20.3%) while ISAba2 was detected in only 6 isolates 
out of 64 (9.4%). The prevalence of ISAba1is comparable with that recorded in 59 isolates 
from Spain40 (93.2%). Lower prevalence rate was recorded in Taiwan39 (36%) and India35 
(33%). The presence of different insertion sequences renders the A. baumannii resistance to 
carbapenems.3 Such insertion sequences located in the proximity of genes coding different 
OXA-types carbapenemases and involved in their overexpression.41
PFGE is one of the most important discriminatory method for A. baumannii and many 
other  pathogens42-44  and an efficient  tool  for  determining the  genetic  relationship  between 
strains isolated from epidemiological situation.45 In the current work, the genetic similarity of 
PFGE types was very high (89 to 100%). The clonal diversity revealed two types of epidemic 
clones: monoclonal and polyclonal. The monoclonal model showed the most common clones 
appear in 12 out of 16 cities. These monoclonal outbreaks were caused by either one or more 
of epidemic PFGE type. The polyclonal model has affected four cites (Riyadh, Almadinah, 
Tabok and Kamis  mosait).  Riyadh is  the  capital  city of  Saudi  Arabia,  that  affected by 9 
different  clones  out  of thirteen.  Almadinah is  the capital  city of  Almadinah province had 
affected by 5 different clones that both cities might cause an explosive outbreaks at different 
time. For Tabok and Kamis Mosait are coexistence clones were clearly in the minority and 
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that could reflect the coexistence of sporadic and epidemic clones.46 Tabok had 2 clones (C2 
and F2) and Kamis Mosait had (J and K) that might reflect low level of hospital infection 
control in these cities. Clone F has been detected in hospitals of Riyadh, Almadinah, Tabok, 
Abha Alrass and Alkafji. Therefore this study point to the transmission of an existent clones 
from one hospital to another one originating a new outbreak in later hospital or may be to the 
health care worker. The possibility of A. baumannii transmission is highly recognized47-49 that 
meaning the reappearance of certain clones within these hospitals reflects endemic persistence 
of this pathogen in diabetic patients, hospital and environments which represent a risk factor 
in future outbreak. A further investigation of these diabetic isolates to be compared with non 
diabetic strains is highly recommended through typing and β-lactamase gene sequencing will 
allow us to establish whether there are particular bacterial  clones that are associated with 
diabetic patients.
Conclusion
The result of the current study revealed that OXA-23 and VIM were the most common 
β-lactamases conferring carbapenem resistance to A. baumannii. In addition, ISAba1 was the 
most  prevalent  insertion sequence.   Moreover,  the current  study provided significant  data 
regarding the clonal diversity of carbapenem resistant A. baumannii in different cites in Saudi 
Arabia. Detection of the certain clone in different cities reflects the horizontal transmission of 
carbapenem resistance. Strict infection control measures should be applied to prevent such 
type of transmission.    
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Table 1    Nucleotide Sequence of primers used in this study
Primer name      Nucleotide Sequence (5`- 3`) Reference
OXA-51-F TAATGCTTTGATCGGCCTTG 22
22OXA-51-R TGGATTGCACTTCATCTTGG
OXA-23-F GATCGGATTGGAGAACCAGA 11
11OXA-23-R ATTCTTGACCGCATTTCCAT
OXA-40-F GGTTGTTGGCCCCCTTAAA 11
11OXA-40-R AGTTGAGCGAAAAGGGGATT
ISAba1-F GTGCTTTGCGCTCATCATGC 23
23ISAba1-R CATGTAAACCAATGCTCACC
ISAba2-F AATCCGAGATAGAGCGGTTC 23
23ISAba2-R TGACACATAACCTAGTGCAC
ISAba3-F CAATCAAATGTCCAACCTGC 23
23ISAba3-R CGTTTACCCCAAACATAAGC
IS18-F CACCCAACTTTCTCAAGATG 23
23IS18-R ACCAGCCATAACTTCACTCG
IMP-F GGAATAGAGTGGCTTAAYTCTC 24
24IMP-R CCAAACYACTASGTTATCT
VIM-F GATGGTGTTTGGTCGCATA 24
24VIM-R CGAATGCGCAGCACCAG
GIM-F TCGACACACCTTGGTCTGAA 24
24GIM-R AACTTCCAACTTTGCCATGC
SPM-F AAAATCTGGGTACGCAAACG 24
24SPM-R ACATTATCCGCTGGAACAGG
SIM-F TACAAGGGATTCGGCATCG 24
24SIM-R TAATGGCCTGTTCCCATGTG
Table 2    Phenotypic characteristics of the tested A. baumannii clinical isolates
Antimicrobial agents Number of isolates (%)
 (n=64)
Sensitive (S) Intermediate (I) Resistant (R)
Imipenem 3 (4.7) 2 (3.1) 59 (92.2)
Meropenem 0 (0) 2 (3.1) 62 (96.9)
Tigecycline 62 (96.9) 2 (3.1) 0
Colistin 62 (96.9) 0 2 (3.1)
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Table 3    Genotypic characteristics of the tested A. baumannii clinical isolates
Characteristic Number of isolates (%)
(n=64)
blaOXA-23 34 (53.1)
blaOXA-40 19 (29.7)
Co existence of both blaOXA-40 and blaOXA-23 0 (0)
Absence of both blaOXA-40 and blaOXA-23 11 (17.2)
blaVIM 59 (92.2)
blaSPM 18 (28.1)
Co existence of both blaVIM and blaSPM 17 (26.6)
blaIMP 0 (0)
blaGIM 0 (0)
BlaSIM 0 (0)
ISAba1 58 (90.6)
ISAba2 6 (9.4)
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ISAba3 13 (20.3)
IS18 0 (0)
Co existence of both ISAba1 and ISAba2 5 (7.8)
Co existence of both ISAba1 and ISAba3 11 (17.2)
Table 4   Profiles of A. baumannii tested isolates  
Hospital location 
(Area)
Clone 
diversity Mechanism of resistant
No. of isolates (%)
(n=64)
RIYADH
A1
A2
B
C1
C3
C4
D2
E
F1
F2
G
H1
H2
M
OXA-23, ISAba1, ISAba2, ISAba3, 
VIM and SPM 34 (53.1)
BREDAH B OXA-23, ISAba1 and VIM 1 (1.6)
ALMADINAH
C1
D2
F1
H2
I
OXA-23, ISAba1, ISAba2, SPM and 
VIM 6 (9.4)
TABOK C2F2 OXA-23, ISAba1 and VIM 5 (7.8)
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ANAK D1 OXA-23 and ISAba1 1 (1.6)
HAIL D1 ISAba1, VIM and SPM 1 (1.6)
ALDAWADME E OXA-23, ISAba1, ISAba2, VIM and SPM 2 (3.1)
ABHA F1 OXA-23, ISAba1, VIM andSPM 1 (1.6)
ALRASS F2 OXA-23, ISAba1 and VIM 1 (1.6)
ALKAFJI F2 OXA-23, ISAba1 and VIM 1 (1.6)
JAZAN H1 OXA-40, ISAba1, ISAba3 and VIM 1 (1.6)
ASEER H1 OXA-40, ISAba1, ISAba3, VIM and SPM 5 (7.8)
SHAGRA I OXA-23, ISAba1 and VIM 1 (1.6)
KAMIS MOSAIT JK OXA-23, ISAba1 and VIM 2 (3.1)
ALQASEEM L ISAba1 and VIM 1 (1.6)
ALAHSA J ISAba1 and VIM 1 (1.6)
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